Clinical trialPhase 2Unknown
Intra-arterial Versus Intravenous Chemotherapy for Locally Advanced Pancreatic Cancer
A Randomized Controlled Phase II Study on Intra-arterial Versus Intravenous Chemotherapy Infusion With Gemcitabine and Oxaliplatin for Locally Advanced Pancreatic Cancer
- Outcome
- Outcome unknown
- Phase
- Phase 2
- Status
- Unknown
- Study type
- Interventional
- Start
- December 2015
- Expected end
- December 2022
- Enrollment
- 168 participants
- Sites
- 1
- Primary outcomes
- Overall survival
- Sponsor
- Other
- Results posted
- No
- Last update
- 5 March 2020
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This study aims to explore the efficacy and safety of intra- arterial infusion of gemcitabine and oxaliplatin in locally advanced pancreatic cancer. This protocol is overseen by the Fudan University Institutional Review Board which has Federal Wide Assurance through the U.S. Department of Health \& Human Services (Approved: April 25, 2002).
Detailed description public domain (ClinicalTrials.gov)
Primary Outcome Measures: To compare the overall survival (OS) in patients with locally advanced pancreatic cancer treated with transcatheter arterial infusion (TAI) of chemotherapeutics or systemic delivered chemotherapy. Secondary Outcome Measures: To compare the progression free survival (PFS), objective response rate (ORR), quality of life (QoL), and adverse effects of treating locally advanced pancreatic cancer patients with TAI or systemic chemotherapy. Exploratory Outcome Measures: To evaluate the correlation between prognosis and expression of serum microRNAs of the patients.
Papers 1
- Registry-listed results paperDigital subtraction angiography-guided pancreatic arterial infusion of GEMOX chemotherapy in advanced pancreatic adenoc… DOI 10.1186/s12885-024-12695-8↗
The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.